Maxim raised the firm’s price target on Nutex Health (NUTX) to $225 from $100 and keeps a Buy rating on the shares. The company’s Q1 results were sharply above consensus as it recognized $105M in revenue from Independent Dispute Resolution arbitration, the analyst tells investors in a research note. Nutex remains on-track to open three de novo mirco-hospitals during 2025, all of which should be “second half of 2025 events”, Maxim adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUTX:
- Clinigence Holdings Reports Robust Growth in Earnings Call
- Nutex Health price target raised to $300 from $150 at Benchmark
- Nutex Health Reports Strong Q1 2025 Financial Growth
- Clinigence Holdings’ Strong Financial Performance and Strategic Successes Drive Buy Rating
- Nutex Health reports Q1 EPS $2.56 vs. (8c) last year